Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants PRIME to SAGE-547 for postpartum depression

Nov. 17, 2016

Albireo Pharma's A-4250 accepted into PRIME program

Nov. 16, 2016

CHMP supports approval of AbbVie's Humira for adolescents with hidradenitis suppurativa

Nov. 15, 2016

EMA's CHMP recommends granting marketing authorization to Afstyla

Nov. 15, 2016

EMA's CHMP recommends approval of Suliqua

Nov. 14, 2016

Ultragenyx Pharmaceutical withdraws conditional MAA from the EMA for Ace-ER

Nov. 14, 2016

EMA gives positive opinion on Gilead's MAA for Vemlidy

Nov. 14, 2016

EMA adopts positive opinion for Novo Nordisk's Fiasp

Nov. 14, 2016

EMA committee hands down positive opinion on Arzerra for relapsed CLL

Nov. 14, 2016

Eloxx Pharmaceuticals reports orphan drug designations for ELX-02 from both FDA and EMA

Nov. 9, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...